SCHEMBL2392613

SCHEMBL2392613

O=C(Nc1ccc(C(=O)O)c(Cl)c1)c1cc2c3c(c1)CCCCC3CCCC2

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CPT2 P23786 2/20 0.45
CPT1A P50416 2/20 0.45
CPT1B Q92523 2/20 0.45
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
NFKB1 P19838 1/20 0.44
HTT P42858 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
SERPINE1 P05121 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
KMT2A Q03164 2/20 0.42
PKM P14618 1/20 0.42
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395262 0.97 CPT2 (0.46) CPT2CPT1ACPT1BNPC1RAB9A
SCHEMBL2398309 0.88 SMN1; SMN2 (0.43) NPC1RAB9ASMN1; SMN2KMT2AKDM4E
SCHEMBL2393108 0.87 KMT2A (0.59) NPC1RAB9ASMN1; SMN2TP53GAA
SCHEMBL2394623 0.86 RARA (0.48) CPT2CPT1ACPT1BNPC1RAB9A
SCHEMBL2392825 0.84 SMN1; SMN2 (0.44) NPC1RAB9ASMN1; SMN2KMT2AKDM4E
SCHEMBL2397423 0.84 KMT2A (0.60) NPC1RAB9ASMN1; SMN2TP53GAA
SCHEMBL2396333 0.84 MCHR1 (0.46) CPT2CPT1ACPT1BNPC1RAB9A
SCHEMBL12316539 0.83 NPC1 (0.41) NPC1RAB9ASMN1; SMN2TP53GAA
SCHEMBL2393053 0.83 MEN1 (0.52) NPC1RAB9ASMN1; SMN2TP53GAA
SCHEMBL2398403 0.83 RARA (0.49) CPT2CPT1ACPT1BNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2189443-B1 TRICYCLIC AMIDE COMPOUND RES FOUND ITSUU LAB (JP) 2013-10-23 EP disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-8232300-B2 Tricyclic amide compound RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2012-07-31 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RESEARCH FOUNDATION ITSUU LABORATORY (JP) 2011-09-01 US disclosed
EP-2189443-A1 TRICYCLIC AMIDE COMPOUND Research Foundation Itsuu Laboratory (JP) 2010-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213157-A1 TRICYCLIC AMIDE COMPOUND RXRA, RXRB, RXRG CPT2 343/4885CPT1A 249/4885CPT1B 437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.